Study details
Enrolling now
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Baylor College of Medicine
NCT IDNCT04740580ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
52
Study length
about 4.9 years
Ages
55–85
Locations
1 site in TX
About this study
Researchers are testing whether supplementing glycine and N-acetylcysteine or alanine as a placebo affects brain metabolism, inflammation, and cognition in people with Alzheimer's disease. The trial will last for 1780 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Alanine
- 2.Glycine
- 3.N-acetylcysteine
PhaseEARLY_Phase 1
DrugAlanine
Routeoral
Primary goalCognition
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Therapeutic Nutrients/Minerals/Electrolytes (Biological Macromolecular Activity), glycine, acetylcysteine
Drug routes
oral (Oral Capsule)
Endpoints
Primary: Cognition
Secondary: Activities of daily living
Body systems
Neurology